Open Protocols

Protocol Name	Investigatory Role	Biomarkers	Data Collections
Clinical and Analytical Validation of Cancer Biomarkers: Developmental Studies	Coordinating	0	0
Clinical Utility of a Single Prostate Health Index Versus Prostate Health Index Kinetics in Predicting Outcomes on Active Surveillance	Involved	0	0
Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection	Involved	1	1
Development and Clinical Validation of Biomarkers for Prostate Cancer	Involved	0	0
Ovarian Cancer Detection by Uterine Lavage DNA and Serum Proteins: A Phase 2 Biomarker Study	Involved	26	0
Prediction rules for aggressive prostate cancer in AS population	Involved	2	0
Prostate-MRI	Involved	0	1
Upgrading Reference Set	Involved	0	0

Closed Protocols

Protocol Name	Investigatory Role	Biomarkers	Data Collections
EDRN-WHI Pre-Clinical Colon Ca Specimens	Involved	0	1
Liver Rapid Reference Set Application: Hemken - Abbott (2015)	Involved	4	0
PCA3 Reference Set Application: T2-Erg-Martin Sanda-Emory (2014)	Involved	2	0
PCA3 Validation Study and Urinary Reference Set	Involved	2	0
Prostate Rapid Pre-Validation Set	Involved	6	0
Prostate Rapid Reference Set Application: Daniel Chan/Patty Beckman- JHU/University of Minnesota (2007)	Leading	5	0
Prostate Reference Set Application: proPSA-Dan Chan-JHU (2008)	Leading	2	0

Publications

Publication Name	PubMed ID	Journal
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.	18550118	J Urol
A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum.	24251762	J Proteome Res
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.	21419439	J Urol
A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma.	30867659	Clin Proteomics
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.	20447916	Cancer Epidemiol Biomarkers Prev
A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient.	19902353	Breast Cancer Res Treat
AISAIC: a software suite for accurate identification of significant aberrations in cancers.	24292941	Bioinformatics
An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors.	28491011	Clin Proteomics
Analysis of serum protein glycosylation by a differential lectin immunosorbant assay (dLISA).	24015777	Clin Proteomics
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.	17981926	Clin Chem
Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.	17982121	Clin Cancer Res
Application of traditional clinical pathology quality control techniques to molecular pathology.	18258922	J Mol Diagn
Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.	28520829	JAMA Oncol
Biomarkers in prostate cancer: what's new?	24626128	Curr Opin Oncol
Can urinary PCA3 supplement PSA in the early detection of prostate cancer?	25385735	J Clin Oncol
Cancer biomarker discovery and translation: proteomics and beyond.	30556752	Expert Rev Proteomics
Cancer biomarker discovery in plasma using a tissue-targeted proteomic approach.	17932335	Cancer Epidemiol Biomarkers Prev
Cancer proteomics: in pursuit of "true" biomarker discovery.	16214905	Cancer Epidemiol Biomarkers Prev
Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.	15596190	Urology
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.	17920110	Gynecol Oncol
Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American men.	15040861	Clin Prostate Cancer
Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.	12384158	Urology
Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides.	26571101	Nat Biotechnol
Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays.	21975078	Anal Chem
Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population.	15076276	J Urol
Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA.	30996714	Clin Proteomics
Enzymes and related proteins as cancer biomarkers: a proteomic approach.	17382922	Clin Chim Acta
Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.	12913682	J Urol
Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.	15613711	Clin Chem
Expression and clinicopathological significance of oestrogen-responsive ezrin-radixin-moesin-binding phosphoprotein 50 in breast cancer.	17593079	Histopathology
Glycoproteomic analysis of bronchoalveolar lavage (BAL) fluid identifies tumor-associated glycoproteins from lung adenocarcinoma.	23802180	J Proteome Res
Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns.	19035787	J Proteome Res
GPQuest: A Spectral Library Matching Algorithm for Site-Specific Assignment of Tandem Mass Spectra to Intact N-glycopeptides.	25945896	Anal Chem
Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid.	16322290	Clin Cancer Res
Identification of glycoproteins containing specific glycans using a lectin-chemical method.	25837443	Anal Chem
Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.	30333219	Cancer Epidemiol Biomarkers Prev
Integrated analyses of proteins and their glycans in a magnetic bead-based multiplex assay format.	23099556	Clin Chem
Integrated glycoprotein immobilization method for glycopeptide and glycan analysis of cardiac hypertrophy.	26378618	Anal Chem
Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance.	28417979	Prostate Cancer Prostatic Dis
Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.	25636659	J Urol
Multiplexed Targeted Mass Spectrometry-Based Assays for the Quantification of N-Linked Glycosite-Containing Peptides in Serum.	26451657	Anal Chem
Network biology in medicine and beyond.	25140061	Circ Cardiovasc Genet
Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers.	19157448	J Urol
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis.	12597929	Urology
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.	27743489	BJU Int
ProteinChips: the essential tools for proteomic biomarker discovery and future clinical diagnostics.	16309362	Clin Chem Lab Med
Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.	15264244	Prostate
Proteomic cancer biomarkers from discovery to approval: it's worth the effort.	24646122	Expert Rev Proteomics
Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay.	16574760	Clin Chem
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.	18024530	Clin Chem
Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers.	25553114	Theranostics
Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.	19484149	Neoplasia
The prostate health index selectively identifies clinically significant prostate cancer.	25463993	J Urol
The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers.	20962299	Cancer Epidemiol Biomarkers Prev
Tissue proteomics using chemical immobilization and mass spectrometry.	25283129	Anal Biochem
Tyramide signal amplification for antibody-overlay lectin microarray: a strategy to improve the sensitivity of targeted glycan profiling.	21133419	J Proteome Res
Updating risk prediction tools: a case study in prostate cancer.	22095849	Biom J
Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer.	22722017	Clin Chim Acta
Validation of a novel model for the early detection of hepatocellular carcinoma.	30675135	Clin Proteomics

Interests

Cancer Biomarkers

The focus of Daniel Chan's research is cancer proteomics. He identifies cancer biomarkers using high throughput approaches, such as mass spectrometry. Once protein markers are identified, antibodies and immunoassays are developed for validation and for clinical studies. Bioinformatics is used to analyze and enhance the clinical usefulness of these biomarkers for the early detection of cancer. Studies are being conducted on patient specimens from prostate, breast, colorectal, ovarian,and other cancers.

To update protocols, publications, biomarkers, or science data, please contact the Data Management and Coordinating Center.

Site

Johns Hopkins Medical Institutions

Degree(s)

Ph.D.

Email

dchan@jhmi.edu

Fax

443-287-6388

Person ID

1760

EDRN Title

EDRN Principal Investigator

Note

To update contact information, please visit the Data Management and Coordinating Center .